Probiotic Bacillus licheniformis ZW3 Alleviates DSS-Induced Colitis and Enhances Gut Homeostasis
-
Published:2024-01-01
Issue:1
Volume:25
Page:561
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Jia Dan12, Li Yingying1, Wang Yingjie1, Guo Yanan1ORCID, Liu Junlong1, Zhao Shuaiyang1, Wang Jinming1ORCID, Guan Guiquan1, Luo Jianxun1, Yin Hong1, Tang Lijie2, Li Youquan13
Affiliation:
1. State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China 2. College of Veterinary Medicine, Northeast Agricultural University, Harbin 150030, China 3. College of Coastal Agricultural Sciences, Department of Veterinary Medicine, Guangdong Ocean University, Zhanjiang 524088, China
Abstract
Despite Bacillus species having been extensively utilized in the food industry and biocontrol as part of probiotic preparations, limited knowledge exists regarding their impact on intestinal disorders. In this study, we investigated the effect of Bacillus licheniformis ZW3 (ZW3), a potential probiotic isolated from camel feces, on dextran sulfate sodium (DSS)-induced colitis. The results showed ZW3 partially mitigated body weight loss, disease activity index (DAI), colon shortening, and suppressed immune response in colitis mice, as evidenced by the reduction in the levels of the inflammatory markers IL-1β, TNF-α, and IL-6 (p < 0.05). ZW3 was found to ameliorate DSS-induced dysfunction of the colonic barrier by enhancing mucin 2 (MUC2), zonula occluden-1 (ZO-1), and occludin. Furthermore, enriched beneficial bacteria Lachnospiraceae_NK4A136_group and decreased harmful bacteria Escherichia-Shigella revealed that ZW3 improved the imbalanced gut microbiota. Abnormally elevated uric acid levels in colitis were further normalized upon ZW3 supplementation. Overall, this study emphasized the protective effects of ZW3 in colitis mice as well as some potential applications in the management of inflammation-related diseases.
Funder
National Beef and Cattle Industry Technology System program for scientific research start-up funds of Guangdong Ocean University Datong County Science and Technology Planning Project Key Research and Development Program of Ningxia Hui Autonomous Region Probiotics Program Science Fund for Creative Research Groups of Gansu Province Agricultural Science and Technology Innovation Program
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference57 articles.
1. Differential diagnosis of inflammatory bowel disease: Imitations and complications;Gecse;Lancet Gastroenterol.,2018 2. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies;Ng;Lancet,2017 3. Holleran, G., Lopetuso, L., Petito, V., Graziani, C., Ianiro, G., McNamara, D., Gasbarrini, A., and Scaldaferri, F. (2017). The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease. Int. J. Mol. Sci., 18. 4. Current and emerging therapeutic targets for IBD;Neurath;Nat. Rev. Gastroenterol. Hepatol.,2017 5. Food and Agriculture Organization, and World Health Organization (2002). Working Group Report on Drafting Guidelines, Evaluation of Probiotics in Food, London, Ontario, Canada, World Health Organization.
|
|